Evotec is a drug manufacturers - specialty & generic business based in the US. Evotec shares (EVO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.17 – a decrease of 2.34% over the previous week. Evotec employs 4,740 staff and has a trailing 12-month revenue of around $797 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.17 |
|---|---|
| 52-week range | $2.84 - $5.68 |
| 50-day moving average | $3.69 |
| 200-day moving average | $3.98 |
| Wall St. target price | $6.45 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.63 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.29 from 2025-05-02
| 1 week (2025-04-28) | -0.23% |
|---|---|
| 1 month (2025-04-04) | 40.20% |
| 3 months (2025-02-06) | -8.72% |
| 6 months (2024-11-06) | 11.00% |
| 1 year (2024-05-06) | -17.50% |
|---|---|
| 2 years (2023-05-05) | -54.48% |
| 3 years (2022-05-05) | 11.93 |
| 5 years (2020-05-06) | 12.0075 |
Valuing Evotec stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Evotec's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Evotec's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $651,000.
The EBITDA is a measure of a Evotec's overall financial performance and is widely used to measure a its profitability.
To put Evotec's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $797 million |
|---|---|
| Operating margin TTM | 0.53% |
| Gross profit TTM | $114.9 million |
| Return on assets TTM | -2.37% |
| Return on equity TTM | -18.92% |
| Profit margin | -24.6% |
| Book value | $5.37 |
| Market Capitalization | $1.5 billion |
TTM: trailing 12 months
We're not expecting Evotec to pay a dividend over the next 12 months.
You may also wish to consider:
Evotec's shares were split on a 4:1 basis on 19 October 2021 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Evotec shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Evotec shares which in turn could have impacted Evotec's share price.
Over the last 12 months, Evotec's shares have ranged in value from as little as $2.84 up to $5.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evotec's is 1.09. This would suggest that Evotec's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Evotec's beta into context you can compare it against those of similar companies.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It also has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital, as well as a strategic research collaboration agreement with Bristol Myers Squibb to build a molecular glue based pipeline for unmet medical needs. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .